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Abstract
In aspiring to become a true engineering discipline for the
biological sciences, the field of synthetic biology has a unique
opportunity to create and encourage the widespread adoption of
standards to enhance innovation and social impact in the field. This
article presents a study of the standards setting efforts by the
institutions, firms, governments, and individuals within the field of
synthetic biology.
Numerous standards have been proposed in synthetic biology,
including those relevant to structure, function, description,
measurement, data, information exchange, software, biosafety and
biosecurity, and even law. At the present time, the adoption of
technical standards has been relatively modest and no one technical
standard appears to have dominated the field. Standards covering
policies in biosecurity, by comparison, are more firmly established
and biosecurity practices governing commercial orders for synthetic
DNA have been widely adopted.
Among standards-setting groups within the synthetic biology
community, most have expressed a preference that standards remain
open and accessible to the community as a whole.
Recent
developments, including the U.S. Supreme Court’s decision in AMP
v. Myriad and the Leahy-Smith America’s Invents Act, could help give
greater clarity to the scope of patent rights covering innovations and
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standards in synthetic biology. Copyright and trademark may
provide alternatives mechanisms for conferring rights in synthetic
biology inventions, setting and reinforcing standards, or promoting
open innovation.
Whether formal policies requiring the disclosure and licensing of
property rights covering technical standards could be made
mandatory or would ultimately be beneficial to the field of synthetic
biology remain open questions. What is certain is that the synthetic
biology community is unusually attuned to debates surrounding
intellectual property and standards setting, and views its engagement
in these debates as vital to ensure the continued success of synthetic
biology.
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INTRODUCTION
In his 1958 Nobel Prize acceptance speech, Edward Tatum
described the application of biology as “the improvement of all living
organisms by processes which we might call biological engineering.”1
“Synthetic biology” has emerged over the past decade as a
presumptive heir to Tatum’s vision. Synthetic biology has developed
two broad emphases.2 One involves the synthesis of large DNA
molecules of specified nucleotide sequence. A competitive industry
of gene synthesis companies has emerged to synthesize made-to-order
DNA molecules on a commercial scale, and speed and cost
improvements of DNA synthesis are making this technology
increasingly accessible. The second emphasis involves the design and
implementation of genetic circuits constructed from basic genetic
components. A distinct feature of synthetic biology is its conscious
reliance on engineering approaches.3 In fact, influences from
engineering, as well as computer science, have led to more
consideration of standards setting, interoperability, and
interchangeability in synthetic biology than is usual in other areas of
biology. Many in the synthetic biology community also support an
ethos of open innovation, and have concerns about the adverse effects
intellectual property rights (primarily patents) could have on the
development of their field.4
Numerous standards have been proposed in synthetic biology,
including those relevant to structure, function, description,
measurement, data, information exchange, software, biosafety and
biosecurity,5 and even law. Adoption of most of these proposed
1. Edward Tatum, Nobel Lecture: A Case History in Biological Research,
NOBELPRIZE.ORG.
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1958/tatumlecture.html (last visited Nov. 9, 2013).
2. Tal Danino, et al., A Synchronized Quorum of Genetic Clocks, 463 NATURE 326
(2010) (explaining how “‘[s]ynthetic biology’ can be broadly parsed into efforts aimed at the
large-scale synthesis of DNA and the forward engineering of genetic circuits from known
biological components”).
3. See, e.g., Drew Endy, Foundations for Engineering Biology, 438 NATURE 449, 449
(2005).
4. See, e.g., Sibylle Gaisser & Thomas Reiss, Shaping the Science-Industry-Policy
Interface in Synthetic Biology, 3 SYST. SYNTH. BIOL. 109, 112 (2009) (stating that "[t]he unclear
patent situation creates a feeling of uneasiness among scientists").
5. The term “biosafety” refers to issues related to the safety of humans, nonhuman
organisms, or ecosystems from the potential for accidental or uncontrolled release of
experimental organisms, standards for which are presented in the NIH Guidelines for Res.
Involving Recombinant or Synthetic Nucleic Acid Molecules (November 2013),
http://oba.od.nih.gov/oba/rac/Guidelines/NIH_Guidelines.pdf. There are also amendments that
modify the scope of the NIH guidelines (announced September 5, 2012). See Dep’t of Health &
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standards has thus far been quite modest.6 A notable exception
involves biosecurity, where standards for screening DNA synthesis
orders have been widely adopted.7 The simultaneous wealth of
proposed standards and dearth of adopted standards may be due, in
part, to the relative youth of the synthetic biology field and its rapid
technical evolution. For example, early enthusiasm for structural and
assembly standards may become less urgent as the technology of
large-molecule DNA synthesis improves. Nevertheless, interest in
standards setting remains a prominent feature of the synthetic biology
field.
A number of organizations have articulated standards setting in
synthetic biology as an important goal. These include the BioBricks
Foundation (BBF),8 the International Genetically Engineered Machine
(iGEM) Foundation,9 the Synthetic Biology Engineering Research
Center (SynBERC),10 BIOFAB: International Open Facility
Advancing Biotechnology (BIOFAB),11 the Synthetic Biology Open
Language (SBOL) Team,12 the Synthetic Biology Standards Network
(SynBioStandards Network),13 the International Association of
Synthetic Biology (IASB),14 the International Consortium for
Polynucleotide Synthesis (ICPS),15 and the Flowers Consortium.16

Human
Servs.,
National
Institutes
of
Health
(Sept.
5,
2012),
http://oba.od.nih.gov/oba/rac/fractions/77_FR_54584.pdf. This report will focus on standards
for “biosecurity” which encompasses safety issues that arise from the potential for intentional or
malevolent release of harmful organisms, whether natural or experimental.
6. Linda J. Kahl & Drew Endy, A Survey of Enabling Technologies in Synthetic Biology,
J. BIOL. ENG. (May 10, 2013), http://www.jbioleng.org/content/7/1/13.
7. See, e.g., Markus Schmidt & Gregor Giersch, DNA Synthesis and Security, in DNA
MICROARRAYS, SYNTHESIS AND SYNTHETIC DNA 285, 297 (Marissa J. Campbell ed., 2011),
available at http://www.markusschmidt.eu/pdf/NOVA-Schmidt-print.pdf (“Despite the coexistence of several guidelines for DNA synthesis (companies), the overall field can be regarded
as being under good control from a security point of view.”).
8. See BIOBRICKS FOUNDATION, http://biobricks.org (last visited Jan. 27, 2014).
9. See IGEM, http://igem.org (last visited Jan. 27, 2014).
10. See
THE
SYNTHETIC
BIOLOGY
ENGINEERING
RESOURCE
CENTER,
http://www.synberc.org (last visited Feb. 1, 2014).
11. See BIOFAB INTERNATIONAL OPEN FACILITY ADVANCING BIOTECHNOLOGY,
http://biofab.org (last visited Feb. 1, 2014).
12. See SYNTHETIC BIOLOGY OPEN LANGUAGE, http://www.sbolstandard.org (last visited
Feb. 1, 2014).
13. See SYNTHETIC BIOLOGY STANDARDS NETWORK, http://www.synbiostandards.co.uk
(last visited Feb. 1, 2014).
14. See INTERNATIONAL ASSOCIATION OF SYNTHETIC BIOLOGY, http://www.iasb.eu/go/synthetic-biology/ (last visited Feb. 1, 2014).
15. Hans Bügl et al., DNA synthesis and biological security, 25 NAT. BIOTECHNOL. 627
(2007) (articulates the recommendations of the International Consortium for Polynucleotide
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Another prominent player has been the U.S. Department of Health
and Human Services, which, in 2010, issued guidance on how to
screen DNA synthesis orders that has been widely adopted by the
DNA synthesis industry.17 At a more informal level, many scientists
and a number of commercial firms have proposed standards relevant
to various aspects of synthetic biology.18 In addition, there has been
considerable interest in standards within the Do-It-Yourself Biology
(DIYbio) movement, whose success in attracting wide participation
may be influenced by the existence of standard components and
protocols capable of use by amateur biologists.19
Many in the synthetic biology community have voiced concerns
that excessive intellectual property rights may have an adverse impact
on the progress of the field.20 In theory, negative effects caused by
patent rights covering commonly used components or methods in
synthetic biology could be exacerbated if those patented components
or methods were to be adopted as standards. However, little evidence
exists to suggest that this is currently the case. In practice, the past
few years have seen tremendous flux in how courts interpret the
patent-eligibility of both methods, such as diagnostic tests, and
components, such as isolated DNA molecules, essential to synthetic
biology. Notably, the Supreme Court invalidated claims to methods
of combined diagnosis and therapy in Mayo v. Prometheus21 and to
isolated genomic DNA in AMP v. Myriad.22 There is a substantial
likelihood that the scope of subject matter in biotechnology currently
considered patent-eligible will narrow, perhaps significantly.
Copyright may be particularly suited to providing an alternative to
patent protection for synthetic DNA, though its applicability to DNA
is currently uncertain.

Synthesis (ICPS) for an oversight framework for research involving commercial DNA
synthesis).
16. See FLOWERS CONSORTIUM, http://www.synbiuk.org (last visited Feb. 1, 2014).
17. Dep’t of Health and Human Servs., Screening Framework Guidance for Providers of
Synthetic Double-Stranded DNA, 75 Fed. Reg. 62,820 (Oct. 13, 2010).
18. See, e.g., Adam Arkin, Setting the Standard in Synthetic Biology, 26 NAT.
BIOTECHNOL. 771 (2008).
19. See, e.g., Todd Kuiken, DIYbio: Low Risk, High Potential, THE SCIENTIST (Mar. 1,
2013), http://www.the-scientist.com/?articles.view/articleNo/34443/title/DIYbio--Low-Risk-High-Potential.
20. See, e.g., Arti Rai & James Boyle, Synthetic Biology: Caught between Property
Rights, the Public Domain, and the Commons, 5 PLOS BIOL. (March 13, 2007),
http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.0050058.
21. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012).
22. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).
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This report resulted from a study of standards setting efforts by
the institutions, firms, governments, and individuals within the field
of synthetic biology. It is based on a review of the relevant published
literature and web-based information. Section I provides a brief
introduction to the field of synthetic biology. Section II surveys
standards, standards setting efforts, and related institutions. Section
III discusses intellectual property issues and rights relevant to
synthetic biology and standards setting. Section IV summarizes the
findings of the report.
I.

OVERVIEW OF SYNTHETIC BIOLOGY

In aspiring to become a true engineering discipline, the field of
synthetic biology differs markedly from most other fields within
biology. During the early days of synthetic biology’s emergence,
Drew Endy suggested standardization, decoupling, and abstraction as
important principles for the engineering of biology.23 He described
standardization as “the definition, description and characterization of
the basic biological parts, as well as standard conditions that support
the use of parts in combination and overall system operation.”24
However, he has also acknowledged the possibility that biology may
be too complex to yield easily to engineering approaches.
Biology differs substantially from the physical and computer
sciences. Biological systems tend to be more complex and less
predictable, making both understanding and (re)designing them
challenging. There may be theoretical limits on the ability to describe
and reconstruct any but the simplest biological systems, with little
prospect of overcoming these limits in the near future.25 In addition,
practical limitations include the difficulty in defining and measuring
the functions of standard biological parts—such as BioBricks, the
unpredictability of genetic circuitry (necessitating exactly the kinds of
trial and error experimentation synthetic biology is meant to avoid),
the challenges posed by biological complexity, the mutual
incompatibility of many standard parts, and the tendency for
variability within biological units to render biological systems prone
to failure.26 For example, synthetic gene networks tend to be resistant
to precisely programmed behavior due to cell-by-cell variability and

23.
24.
25.
26.

Endy, supra note 3, at 450.
Id.
Christof Koch, Modular Biology Complexity, 337 SCIENCE 531 (2012).
Roberta Kwok, Five Hard Truths for Synthetic Biology, 463 NATURE 288 (2010).
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intrinsic stochasticity.27 Jesse Stricker urged “caution must be
exercised when making simplifying assumptions in the design of
engineered gene circuits.”28
The applied nature of synthetic biology has resulted in a small
industry that is rapidly evolving.29 Commercial synthetic biology
represents a modest fraction of the biotechnology industry, and firms
have experienced mixed success. Among the most prominent are
DNA 2.0, Inc.,30 and Blue Heron Biotech, LLC,31 providers of
synthetic genes; Amyris, Inc.,32 which engineered a pathway for
synthesizing a precursor to the anti-malarial artemisinin; LS9, Inc.
(recently acquired by Renewable Energy Group, Inc.)33 and Qteros,
Inc.,34 developers of biofuels; Ginkgo BioWorks,35 a biological
engineering company; and Synthetic Genomics, Inc., a developer of
synthetic genomics technologies, such as Gibson Assembly,36 and
owner of a substantial patent portfolio.37 Codon Devices, Inc., an
early DNA synthesis firm, went bankrupt in 2009,38 although a new
venture, Gen9, Inc., has since emerged and is developing technology
to support synthesis and assembly of larger DNA constructs.39
A prevalent theme within the synthetic biology community is the
value of an open science ethos.40 This ethos often promotes open

27.
28.

Danino et al., supra note 2.
Jesse Stricker et al., A Fast, Robust and Tunable Synthetic Gene Oscillator, 456
NATURE 516 (2008).
29. SYNBIOBETA, http://synbiobeta.com (last visited Jan. 30, 2014).
30. DNA 2.0, INC., https://www.dna20.com (last visited Jan. 30, 2014).
31. BLUE HERON BIOTECH, LLC, http://www.blueheronbio.com (last visited Jan. 30,
2014).
32. AMYRIS, INC., http://www.amyris.com (last visited Jan. 30, 2014).
33. Press Release, Renewable Energy Group, Inc., Renewable Energy Group Enters
Indus. Biotech with Acquisition of LS9 (Jan 22, 2014), available at
http://www.regi.com/news/2014/01/22/renewable-energy-group-enters-industrial-biotechacquisition-ls9.
34. QTEROS, INC., http://www.qteros.com (last visited Jan. 30, 2014).
35. GINGKO BIOWORKS, http://ginkgobioworks.com (last visited Jan. 30, 2014).
36. SGI-DNA, http://www.sgidna.com/products.php. (last visited Jan. 27, 2014).
37. Among the patent applications owned by Synthetic Genomics, Inc. are U.S. Patent
No. 20070122826 (filed Oct. 12, 2006) (“Minimal Bacterial Genome”); U.S. Patent No.
20070264688 (filed Dec. 6, 2006) (“Synthetic Genomes”); and U.S. Patent No. 20110053273
(filed May 19, 2010) (“Methods for Cloning and Manipulating Genomes”).
38. Todd Wallack, Codon Devices Closing as Financing Dwindles, THE BOSTON GLOBE
(April
3,
2009),
http://www.boston.com/business/healthcare/articles/2009/04/03/codon_devices_closing_as_fina
ncing_dwindles/.
39. GEN 9, INC., http://www.gen9bio.com (last visited Jan. 30, 2014).
40. Stephen M. Maurer, Before It’s Too Late – Why Synthetic Biologists Need an Open-
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sharing of information among biologists as well as considerable
attention to the effects that patent rights may have on the evolution of
the field. For example, the BioBricks Foundation and the iGEM
Foundation have tended to promote open sharing of both parts and
information, while trying to develop methods for detecting and
avoiding patents that might interfere with such openness.41 However,
it appears highly likely that universities and firms have already
acquired considerable patent rights in various aspects of synthetic
biology—patent rights that could interfere with open science
practices.42 Thus far, there is little evidence that patents covering
aspects of synthetic biology have, in fact, been used in this manner.
One notable feature of standards setting and intellectual property
in synthetic biology is the recurring participation of a relatively small
group of academic scientists, a substantial minority of them with
formal training as engineers, who have serially founded and led many
of the institutions noted above.
II. STANDARDS AND STANDARDS-SETTING IN SYNTHETIC BIOLOGY
A. Technical Standards
Within the synthetic biology community, researchers are actively
working to develop technical standards for genetically encoded
functions that will enable the efficient production, distribution and reuse of biological parts. To date, technical standards relevant to
synthetic biology applications are being developed in at least four
broad categories: physical composition, functional composition, units
of measurement, and data exchange.43
Physical composition standards support the physical assembly of
Parts Collaboration – and How to Build One, 10 EMBO REPORTS 806 (2009); Joachim Henckel
& Stephen M. Maurer, The Economics of Synthetic Biology, MOL. SYST. BIOL., June 5, 2007,
available at http://www.nature.com/msb/journal/v3/n1/full/msb4100161.html; David Cohn,
Open-Source
Biology
Evolves,
WIRED
(Jan.
17,
2005),
http://www.wired.com/medtech/health/news/2005/01/66289?currentPage=all.
41. An example of this is the development by the BioBricks Foundation of the BioBrick
User and Contributor Agreements, together, the BioBrick Public Agreement (BPA), The
BioBrick Public Agreement (BPA), BIOBRICKS FOUNDATION, https://biobricks.org/bpa/ (last
visited Feb. 18, 2014), and the requirement that all participants in the iGEM competition
contribute the parts they make to the iGEM Registry of Standard Biological Parts. See What
about these standard parts?, IGEM, http://igem.org/About (last visited March 4, 2014).
42. Sapna Kumar & Arti Rai, Synthetic Biology: The Intellectual Property Puzzle, 85
TEX. L. REV. 1745 (2007); Davy van Doren, Stefan Koenigstein, & Thomas Reiss, The
Development of Synthetic Biology: A Patent Analysis, 7 SYST. SYNTH. BIOL. 209-20 (2013).
43. See Technical
Standards
Framework,
BIOBRICKS
FOUNDATION,
http://biobricks.org/programs/technical-standards-framework (last visited Jan. 27, 2014).
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individual biological parts into multi-component systems. One of the
earliest examples of a physical composition standard in synthetic
biology is the original BioBrick assembly standard (BBF RFC 10),
which uses iterative restriction enzyme digestion and ligation
reactions to assemble small biological parts into larger composite
parts.44 This standard initially served as the primary means for
physical assembly of biological parts by teams participating in the
iGEM competition,45 and thousands of parts in the iGEM Registry of
Standard Biological Parts46 have been constructed following this
standard. As technology has advanced, the BioBrick assembly
standard has undergone a number of refinements and other physical
composition standards that provide additional flexibility for the
physical assembly of biological parts have been introduced.47
Although the BioBrick assembly standard and other methods that
build upon this standard have proven useful to many groups,48 it is

44. Thomas Knight, Idempotent Vector Design for Standard Assembly of BioBricks (MIT
Artificial Intelligence Lab. & MIT Synthetic Biology Working Grp., 2003), available at
http://hdl.handle.net/1721.1/21168.
45. IGEM, supra note 9.
46. See Registry of Standard Biological Parts, IGEM, http://parts.igem.org/Main_Page
(last visited March 4, 2014).
47. See, e.g., Ira Phillips & Pamela Silver, BBF RFC 23: A New BioBrick Assembly
Strategy Designed for Facile Protein Engineering, DSPACE@MIT (Apr. 18, 2006),
http://hdl.handle.net/1721.1/32535; Thomas Knight, BBF RFC 2: Draft Standard for BioBrick
BB-2 Biological Parts, DSPACE@MIT (Nov. 19, 2008), http://hdl.handle.net/1721.1/45139;
Reshma P. Shetty, Drew Endy & Thomas F. Knight, Engineering BioBrick Vectors from
BioBrick Parts, J. BIOL. ENG. (April 14, 2008), http://www.jbioleng.org/content/2/1/5; Michael
Ellison et al., BBF RFC 47: BioBytes Assembly Standard, DSPACE@MIT (Oct. 29, 2009),
http://hdl.handle.net/1721.1/49518; Katja Arndt et al., BBF RFC 25: Fusion Protein (Freiburg)
BioBrick
Assembly
Standard,
DSPACE@MIT
(Apr.
18,
2009),
http://hdl.handle.net/1721.1/45140; Sergio G. Peisajovich et al., BBF RFC 28: A Method for
Combinatorial Multi-Part Assembly Based on the Type IIs Restriction Enzyme AarI,
DSPACE@MIT (Sept. 16, 2009), http://hdl.handle.net/1721.1/46721; J. Christopher Anderson et
al., BglBricks: A Flexible Standard for Biological Part Assembly, J. BIOL. ENG. (Jan. 20, 2010),
http://www.jbioleng.org/content/4/1/1; Sean C. Sleight et al., In-Fusion BioBrick Assembly and
Re-engineering, 38 NUCLEIC ACIDS RES. 2624 (2010); Reshma Shetty et al., Assembly of
BioBrick Standard Biological Parts Using Three Antibiotic Assembly, 498 METHODS ENZYMOL.
311 (2011).
48. See, e.g., Karmella A. Haynes et al., Engineering Bacteria to Solve the Burnt Pancake
Problem, J. BIOL. ENG. (May 20, 2008), http://www.jbioleng.org/content/2/1/8; Bruno Afonso et
al., A Synthetic Circuit for Selectively Arresting Daughter Cells to Create Aging Populations, 1
NUCLEIC ACIDS RES. 2727 (2010); Raik Grunberg et al., Building Blocks for Protein Interaction
Devices, 38 NUCLEIC ACIDS RES. 2645 (2010); Hsin-Ho Huang et al., Design and
Characterization of Molecular Tools for a Synthetic Biology Approach towards Developing
Cyanobacterial Biotechnology, 38 NUCLEIC ACIDS RES. 2577 (2010); Marco Constante et al., A
Biobrick Library for Cloning Custom Eukaryotic Plasmids, PLOS ONE (August 25, 2011),
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0023685; Elisabeth
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now possible to assemble biological parts without the use of
restriction enzymes. Methods such as Gibson Assembly,49 Seamless
Ligation Cloning Extract (SLiCE),50 and others,51 enable the seamless
construction of large DNA molecules and do not impose sequence
constraints on the design of biological parts. Yet another approach,
often used in conjunction with other physical assembly methods, is de
novo DNA synthesis.52 With continued improvements in the capacity
to synthesize DNA constructs at ever more affordable prices, de novo
synthesis of multicomponent devices and systems may become
feasible.53 So far, no single approach has become a de facto standard
for the physical assembly of biological parts and physical
composition standards will likely continue to evolve.54
Functional composition standards support the ability of
assembled biological parts to function in a predictable manner. As an
example, the Expression Operating Unit (EOU) is a genetic layout
architecture that enables forward engineering at the genome scale by
ensuring that independent expression elements perform reliably
across different genetic contexts.55 Other tools that help rationally

Linton et al., Translocation of Green Fluorescent Protein by Comparative Analysis with
Multiple Signal Peptides, 7 BIOTECHNOL. J. 667 (2012); Raul Cuero, J. Lilly & David S.
McKay, Constructed Molecular Sensor to Enhance Metal Detection by Bacterial Ribosomal
Switch-Ion Channel Protein Interaction, J. BIOTECHNOL., March 2012, at 1; Liping Du et al.,
Multigene Expression In Vivo: Supremacy of Large Versus Small Terminators for T7 RNA
Polymerase, 109 BIOTECHNOL. & BIOENG. 1043 (2012).
49. Daniel G. Gibson et al., Enzymatic Assembly of DNA Molecules up to Several
Hundred Kilobases, 6 NAT. METHODS 343 (2009).
50. Yongwei Zhang et al., SLiCE: A Novel Bacterial Cell Extract-Based DNA Cloning
Method, 40 NUCLEIC ACIDS RES. e55 (2012).
51. See, e.g., Baogong Zhu et al., In-Fusion Assembly: Seamless Engineering of
Multidomain Fusion Proteins, Modular Vectors, and Mutations, 43 BIOTECHNIQUES 354
(2007); Carola Engler et al., A One Pot, One Step, Precision Cloning Method with High
Throughput
Capability,
PLOS
ONE
(Nov.
5,
2008),
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0003647;
Jiayuan
Quan & Jingdong Tian, Circular Polymerase Extension Cloning of Complex Gene Libraries and
Pathways,
PLOS
ONE
(July
30,
2009),
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0006441; Patrick M.
Boyle et al., A BioBrick Compatible Strategy for Genetic Modification of Plants, 6 J. BIOL. ENG.
8 (2012); Arjen J. Jakobi & Eric G. Huizinga, A Rapid Cloning Method Employing Orthogonal
End
Protection,
PLOS
ONE
(June
7,
2012),
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0037617.
52. Peter A. Carr & George M. Church, Genome Engineering, 27 NAT. BIOTECHNOL.
1151 (2009).
53. Robert Carlson, The Changing Economics of DNA Synthesis, 27 NAT. BIOTECHNOL.
1091 (2009).
54. Kahl, supra note 6.
55. Vivek K. Mutalik et al., Precise and Reliable Gene Expression via Standard
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predict the modulators of gene expression, such as the ribosome
binding site (RBS) calculator56 and calculators for promoter
strength,57 also are useful as an approach for the functional
composition of assembled biological parts and devices.
Standards for units of measurement enable independent
researchers to make measurements of genetically encoded functions
that account for variation introduced by differences in experimental
conditions and instruments. They are also sharable across multiple
laboratories. As an example, the Relative Promoter Unit (RPU) is a
standard unit for reporting promoter activity, where RPU is defined as
a ratio of the absolute activity of a sample promoter relative to the
absolute activity of a standard reference promoter.58 Because the
RPU is a relative measure, as opposed to an absolute measure, it is
not tied to a single measurement procedure and so different
laboratories are free to select whatever procedures they find most
convenient and suitable. The concept of the RPU was initially
demonstrated using promoters in E. coli, and has since been extended
for promoter characterization in mammalian cells.59
Another
measurement standard that has been proposed is Polymerase Per
Second, or PoPS.60 Conceptually similar to the current in a wire that
connects two electronic components, PoPS represents the flow of
RNA polymerase molecules along the DNA.61 By defining PoPS as
the number of times that an RNA polymerase molecule passes a
specific point on DNA per unit time, PoPs provides a measure of
transcription rate and can be used to characterize molecular devices
such as genetic circuits.62
Transcription and Translation Initiation Elements, 10 NAT. METHODS 354 (2013).
56. Howard M. Salis, Ethan A. Mirsky & Christopher A. Voigt, Automated Design of
Synthetic Ribosome Binding Sites to Control Protein Expression, 27 NAT. BIOTECHNOL. 946
(2009).
57. Virgil A. Rhodius, Vivek K. Mutalik & Carol A. Gross, Predicting the strength of
UP-elements and full-length E. coli E promoters, 40 NUCLEIC ACIDS RES. 2907 (2012).
58. Jason R. Kelly et al., Measuring the Activity of BioBrick Promoters Using an In Vivo
Reference Standard, J. BIOL. ENG. (March 20, 2009), http://www.jbioleng.org/content/3/1/4.
59. Lars Velten et al., Units for Promoter Measurement in Mammalian Cells,
DSPACE@MIT (Oct. 21, 2009), http://hdl.handle.net/1721.1/49501.
60. For a colorful and amusing description of PoPS, the reader is referred to a comic book
authored by Drew Endy and Isadora Deese and illustrated by Chuck Wadey. Drew Endy &
Isadora Deese, Adventures in Synthetic Biology, MIT SYNTHETIC BIOLOGY WORKING GROUP,
http://mit.edu/endy/www/scraps/comic/AiSB.vol1.pdf (last visited Feb. 19, 2014).
61. Id.
62. Prasanna Amur Varadarajan & Domitilla Del Vecchio, Design and Characterization
of a Three-Terminal Transcriptional Device through Polymerase Per Second, IEEE TRANS.
NANOBIOSCIENCE, Sept. 2009, at 281 (describing PoPS as analogous to an electrical current, and
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Data exchange standards enable researchers to query and retrieve
information needed to more efficiently design new biological parts,
devices, and systems for synthetic biology applications. As an
example, Synthetic Biology Open Language (SBOL) is a software
standard for the electronic exchange of specifications and descriptions
of genetic parts, devices, modules, systems, and engineered
genomes.63 The SBOL semantic was used to create the Standard
Biological Parts Knowledgebase (SBPkb), which has been populated
with the 13,000 parts from the iGEM Registry of Standard Biological
Parts and is anticipated to serve as the first node in a framework for a
semantic web of distributed knowledge in synthetic biology. 64 In
addition, SBOL visual (SBOLv) has been proposed as a graphical
notation standard for the visual display of information about the
physical composition of basic and composite parts used in the
development of biological devices.65 Additional standardization
efforts for data exchange have focused on the development of
datasheets that describe the formal specifications for basic and
composite parts, and example datasheets summarizing the relevant
physical characteristics and performance features of biological parts
have been proposed.66
B. Technical Standards-Setting Organizations
As in other engineering disciplines, standards are best developed
by consensus and this is no less true in synthetic biology (Table 1).67
An organizational framework to help define, evaluate, and propose
technical standards in synthetic biology has been created by the
BioBricks Foundation.68 This framework, known as the BioBrick
Request for Comments (RFC) process, has been instrumental in

characterizing a three-terminal transcriptional device using PoPS as input and output).
63. SBOL
Team,
SYNTHETIC
BIOLOGY
OPEN
LANGUAGE,
http://www.sbolstandard.org./community (last visited Jan 27, 2014).
64. Michal Galdzicki et al., Standard Biological Parts Knowledgebase, PLOS ONE (Feb.
24, 2011), http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0017005.
65. Jacqueline Quinn et al., BBF RFC 93: Synthetic Biology Open Language Visual
(SBOLv) version 1.0.0, DSPACE@MIT (March 31, 2013), http://hdl.handle.net/1721.1/78249.
66. See, e.g., Barry Canton, Anna Labno & Drew Endy, Refinement and Standardization
of Synthetic Biological Parts and Devices, 26 NAT. BIOTECHNOL. 787 (2008); Taek S. Lee et al.,
BglBrick Vectors and Datasheets: A Synthetic Biology Platform for Gene Expression, J. BIOL.
ENG. (Sept. 20, 2011), http://www.jbioleng.org/content/5/1/12; Kenneth Evan Thompson et al.,
SYNZIP Protein Interaction Toolbox: In Vitro and In Vivo Specifications of Heterospecific
Coiled-Coil Interactions Domains, 1 ACS SYNTH. BIO. 118 (2012).
67. See infra Table 1.
68. BIOBRICKS FOUNDATION, supra note 8.
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facilitating discussion and coordinating the efforts of multiple
researchers in technical standards development.69 Initiated in 2008,
the BioBrick RFC process was inspired by and modeled upon the
RFC process of the Internet Engineering Task Force, and currently
contains over 100 technical documents.70 These documents may
propose a technical standard, describe best practices or protocols, or
simply provide information.71 As new BioBrick RFCs are added,
they may comment upon, extend, or replace earlier RFCs. In this way
the BioBrick RFC process serves as a convenient, useful vehicle for
documenting and distributing information so that a general consensus
may eventually emerge and lead to the widespread adoption of
technical standards.
Technical standards development efforts also have been initiated
by the BIOFAB. The concept for creating a BIOFAB was initially
proposed in 2006.72 Drawing upon analogies to the semiconductor
industry, the idea was put forth that a fabrication platform using
standardized methods and libraries of compatible biological parts
could empower engineers to design and build sophisticated biological
devices and systems with greater efficiency and speed than is possible
using conventional molecular biology approaches.73 Towards that
end, the world’s first biological design-build facility was founded in
2009 and located in Emeryville, California.74 Funded by a 2-year
grant from the National Science Foundation, the Emeryville BIOFAB
was operated in partnership with Lawrence Berkeley National
Laboratory, the BioBricks Foundation, and SynBERC.75 There, the
BIOFAB team developed a mathematical framework for quantifying
the intrinsic activities of genetic elements and designed a genetic
69. See RFC Process, BIOBRICKS FOUNDATION, http://biobricks.org/programs/technicalstandards-framework/ (last visited Feb. 1, 2014).
70. A listing of assigned RFC numbers and documents may be found at The BioBricks
Foundation:
RFC,
OPENWETWARE,
http://openwetware.org/wiki/The_BioBricks_Foundation:RFC#BBF_RFC_0:_Instructions_to_B
BF_RFC_Authors (last visited Jan. 30, 2014).
71. Daniel Tarjan et al., BBF RFC 0: Instructions to BBF RFC Authors, DSPACE@MIT
(Nov. 10, 2008), http://hdl.handle.net/1721.1/44960.
72. David Baker et al., Engineering Life: Building a FAB for Biology, SCI. AM., June
2006, at 44.
73. BIOFAB, supra note 11.
74. Id.
75. The Emeryville BIOFAB facility maintains a neutral posture with respect to
intellectual property rights so that the facility will be able to support partnerships with academic
and commercial entities, some of whom might work with the BIOFAB in developing both
improved open access and propriety parts. See SynBERC Parts on Demand, BIOFAB,
http://biofab.org/projects (last visited Jan. 30, 2014).
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layout architecture to help eliminate the functional uncertainty that
arises from the reuse of transcription and translation control elements
with sequence-distinct protein coding regions.76 A second BIOFAB,
founded at Stanford University in 2012 and supported by the
BioBricks Foundation, aims to map the central dogma of yeast and
contribute standardized biological parts to the public domain.77 The
BioBricks Foundation aspires to build a network of BIOFABs around
the world to create synergy and foster the development of
community-driven technical standards and production of standardized
biological parts.78
Additional efforts in technical standards development have been
initiated by the SBOL Team.79 Development of the SBOL standard
began in 2008 (then in a format known as Provisional BioBrick
Language, or PoBoL),80 and this community-based effort has
consistently grown in size and sophistication as the SBOL standard
continues to evolve to meet the needs of synthetic biology researchers
and engineers.81 The core data model for the SBOL standard supports
organization of the essential information for synthetic DNA
sequences,82 and extensions to the core data model support
visualization of biological designs and the communication of
additional information.83 The SBOL standard underlies the SBPkb,
which is a semantic web resource that allows researchers to query and
retrieve information about biological parts from the iGEM Registry of

76. Vivek K. Mutalik et al., Quantitative Estimation of Activity and Quality for
Collections of Functional Genetic Elements, 10 NAT. METHODS 347 (2013); Mutalik, supra note
55.
77. See
Stanford
BIOFAB,
BIOBRICKS
FOUNDATION,
http://biobricks.org/programs/technical-program (last visited Jan. 30, 2014).
78. See
Global
BIOFAB
Network,
BIOBRICKS
FOUNDATION,
http://biobricks.org/programs/technical-program (last visited Jan. 30, 2014).
79. SBOL is an open-specification, open-source project in which a diverse community of
individuals from academia, industry and public benefit organizations work collaboratively to
create data exchange standards for describing and communicating information about genetic
parts, devices, modules, and systems. See SYNTHETIC BIOLOGY OPEN LANGUAGE, supra note
12.
80. Michal Galdzicki et al., BBF RFC 31: Provisional BioBrick Language (PoBoL),
DSPACE@MIT (May 15, 2009), http://hdl.handle.net/1721.1/45537.
81. Michael Galdzicki et al., BBF RFC 87: Synthetic Biology Open Language (SBOL)
Version 1.1.0., DSPACE@MIT (Oct. 11, 2012), http://hdl.handle.net/1721.1/73909.
82. Jean Peccoud et al., Essential Information for Synthetic DNA Sequences, 29 NAT.
BIOTECHNOL. 22 (2011).
83. Quinn, supra note 65; Jeffrey Johnson et al., BBF RFC 68: Standard for the
Electronic Distribution of SBOLv Diagrams, DSPACE@MIT (Dec. 05, 2010),
http://hdl.handle.net/1721.1/60086.
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Standard Biological Parts.84 Similarly, the Joint BioEnergy Institute
Inventory of Composable Elements (JBEI-ICE), a public registry of
biological parts developed by the Joint BioEnergy Institute, supports
the SBOL data exchange standard.85 In addition, several SBOLcompliant software tools have been developed for synthetic biology
(Table 2).86
Synthetic biology standards also have been addressed by the
Synthetic Biology Standards Network (SynBioStandards Network),
an interdisciplinary network for UK academics working in synthetic
biology.87 Though it does not consider itself to be a standards setting
organization, the SynBioStandards Network aims to develop a
common language among researchers from the fields of engineering,
biological sciences, computer science, and the social sciences and to
develop approaches, tools, and protocols that may become gold
standard and adopted by synthetic biology researchers worldwide.88
Standards setting efforts have been prominent throughout the
development of synthetic biology, at least in part due to participation
in the field by engineers, computer scientists, and others who are
familiar and comfortable with technical standards.89 One worry has
been that the imposition of standards too early in the evolution of
synthetic biology might canalize the trajectory of the field,
discouraging alternative directions and impeding innovation.
However, little evidence exists to support this worry. None of the
technical standards proposed thus far have been made mandatory for
the field as a whole, and no governance body with the authority to
impose mandatory technical standards for synthetic biology has yet
been established. In fact, even the most promising technical standards

84. Galdzicki, supra note 64.
85. Timothy S. Ham et al., Design, Implementation and Practice of JBEI-ICE: An Open
Source Biological Part Registry Platform and Tools, 40 NUCLEIC ACIDS RES. e141, (2012),
available at http://nar.oxfordjournals.org/content/40/18/e141.full.pdf+html.
86. A vast array of software tools have been developed for synthetic biology, some of
which are SBOL-compliant. See infra Table 2. For recent review see Adrian L. Slusarczyk,
Allen Lin & Ron Weiss, Foundations for the Design and Implementation of Synthetic Genetic
Circuits, 13 NATURE 406 (2012).
87. The SynBioStandards Network was funded for three years beginning in June 2008 by
the Arts & Humanities Research Council, the Biotechnology and Biological Sciences Research
Council, Economic & Social Research Council, and the Engineering and Physical Sciences
Research Council. See About the SynBioStandards Network, SYNTHETIC BIOLOGY STANDARDS
NETWORK, http://www.synbiostandards.co.uk/about.php (last visited Feb. 19, 2014).
88. Id.
89. Adam Arkin, Setting the Standard in Synthetic Biology, 26 NAT. BIOTECHNOL. 771
(2008); Arti Rai, Unstandard Standarization: The Case of Biology, 53 COMMS. ACM 37 (2010).
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seem to have served in a transitory capacity given the speed at which
scientific and technical advances in synthetic biology occur. For
example, a number of proposed technical standards pertaining to the
physical assembly of DNA fragments into larger DNA molecules are
being displaced by distinctly different methods, such as Gibson
Assembly and de novo DNA synthesis.90
The iterative and
progressive nature of technical standards development has been
embraced by the synthetic biology research community, as evidenced
by the BioBricks Foundation’s RFC process, which provides an
avenue for the improvement, and even outright replacement, of earlier
proposed technical standards.91 Only in the realm of biosecurity has
any standard risen to the level of wide acceptance within the synthetic
biology community, and there, the primary proponent of the standard
adopted was the U.S. federal government. At the present time,
standards setting efforts do not appear to have affected the
development of synthetic biology adversely.
Table 1. Standard Setting Organizations and Intellectual
Property Policies in Synthetic Biology
Standards
Setting
Organization
BioBrick
Request For
Comments
(RFC) process
Started: 2006

Example Technical
Standards
Physical Composition:
BioBrick standard
(BBF RFC 10)
BglBrick standard
(BBF RFC 21)
BioFusion standard
(BBF RFC 23)
Freiburg standard
(BBF RFC 25)
AarI cloning standard
(BBF RFC 28)
Units of Measure:
Relative Promoter Unit (RPU)
(BBF RFC 19)
Relative Mammalian Promoter
Unit (RMPU)
(BBF RFC 41)

90.
91.

Kahl, supra note 6.
RFC Process, supra note 69.

Intellectual Property
Policy
The BioBricks
Foundation advocates
open technology
platforms and technical
standards, and
encourages the donation
of basic bioengineering
knowledge into the
public domain.
The BioBricks
Foundation does not
hold any patents relating
to technical standards
and retains copyright to
documents filed in the
BioBrick RFC process.
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Table 1. (continued)
Standards
Setting
Organization
Synthetic
Biology Open
Language
(SBOL) Team

Example Technical
Standards
Data Exchange:
Synthetic Biology Open
Language (SBOL)

Intellectual Property
Policy
SBOL is an openspecification, opensource, communitybased project.

SBOL visual (SBOLv)
SBOL has been
submitted to the
BioBrick RFC process
(BBF RFC 87) as a
software standard for the
electronic exchange of
specifications and
descriptions of genetic
parts, devices, modules,
systems, and engineered
genomes.

Started: 2008

SBOLv has been
submitted to the
BioBrick RFC process
(BBF RFC 93) as a
graphical notation to
support the description
and specification of
genetic designs.
BIOFAB:
International
Open Facility
Advancing
Biotechnology
(BIOFAB)
Started: 2009

Functional Composition:
Expression Operating Unit
(EOU)

The Emeryville
BIOFAB facility
maintains a neutral
posture with respect to
intellectual property
rights so that the facility
will be able to support
partnerships with
academic and
commercial entities.
The Stanford BIOFAB
aims to contribute parts
to the public domain.
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Table 2. SBOL-Compliant Software tools for Synthetic
Biology
Software Tool

Bacillo
92
Bricks

Benchling

93

Clotho

DeviceEditor

95

Eugene

Gene
96
Designer

94

Description

URL

A catalogue of Bacillus subtilis
virtual parts, provided in the
form of mathematical models
that can be composed to create
genetic circuits.
Enables design, analysis and
sharing of sequence data in the
cloud.

http://intbio.ncl.ac.uk/?
projects=standardvirtual-parts

A data model-based tool and
plugin environment that
provides a data model for
representing biological objects,
a common API for
manipulating these objects, and
a common platform for
developing Apps for designing
synthetic biological systems.
A web-based visual design
environment that mimics the
intuitive visual whiteboard
design process practiced in
biological laboratories.
A human- and machinereadable language for the
specification of biological
constructs.
A software tool for designing
DNA sequences de novo

http://www.clothocad.o
rg

https://benchling.com

http://j5.jbei.org

http://eugenecad.org

https://www.dna20.co
m/genedesigner

92. Goksel Misirli et al., BacillOndex: An Integrated Data Resource for Systems and
Synthetic Biology, 10 J. INTEGRATED BIOINFORMATICS 224 (2013).
93. Bing Xia et al., Developer’s and User’s Guide to Clotho v2.0: A software platform
for the creation of synthetic biological systems, 498 METH. ENZYMOL. 97 (2011).
94. Joanna Chen et al., DeviceEditor Visual Biological CAD Canvas, J. BIOL. ENG. (Feb.
28, 2012), http://www.jbioleng.org/content/6/1/1.
95. Lesia Bilitchenko et al., Eugene – A Domain Specific Language for Specifying and
Constraining Synthetic Biological Parts, Devices, and Systems, PLOS ONE (April 29, 2011),
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0018882.
96. Alan Villalobos et al., Gene Designer: A Synthetic Biology Tool for Constructing
Artificial DNA Segments, 7 BMC BIOINFORMATICS 285 (2006).
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Table 2. (continued)
Software Tool

GenoCAD

97

98

iBioSim

99

j5

JBEI-ICE

100

101

MoSeC

Proto
102
BioCompiler

Description
A web-based application to
design protein expression
vectors, artificial gene network,
and other genetic constructs
A project-based tool for the
analysis of genetic
circuits,metabolic networks,
cell signaling pathways and
other biological and chemical
systems.
A web-based software tool to
automate the design of scar-less
multipart DNA assembly
protocols
An open source registry
platform for managing
information about biological
parts.
A Java application for synthetic
biology design that takes a
model annotated with the DNA
sequence information of genetic
elements and converts it into a
DNA sequence
A platform for biological
system designers to express
desired system functions using
a user-friendly, high-level,
biologically-focused
programming language.

URL
http://genocad.org

http://www.async.ece.u
th.edu/iBioSim

http://j5.jbei.org

https://publicregistry.jbei.org

http://intbio.ncl.ac.uk/?
projects=mosec

http://proto.bbn.com/co
mmons/

97. Michael J. Czar, Yizhi Cai & Jean Peccoud, Writing DNA with GenoCAD, NUCLEIC
ACIDS
RES.
(May
8,
2009),
http://nar.oxfordjournals.org/content/37/suppl_2/W40.full?sid=d98aeb4e-4f35-4e8e-939d967a5ea028cc.
98. Chris J. Myers et al., iBioSim: A Tool for the Analysis and Design of Genetic Circuits,
25 BIOINFORMATICS 2848 (2009).
99. Nathan J. Hillson, Rafael D. Rosengarten & Jay D. Keasling, j5 DNA Assembly
Design Automation Software, 1 ACS SYNTHETIC BIOL. 14 (2012).
100. Ham, supra note 85.
101. Goksel Misirli et al., Model Annotation for Synthetic Biology: Automating Model to
Nucleotide Sequence Conversion, 27 BIOINFORMATICS 973 (2011).
102. Jacob Beal, Ting Lu & Ron Weiss, Automatic Compilation from High-Level
Biologically-Oriented Programming Language to Genetic Regulatory Networks, PLOS ONE
(August
5,
2011),
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022490.
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Table 2. (continued)
Software Tool

103

SBPkb

TeselaGen

TinkerCell

104

Description

URL

A semantic web resource that
allows researchers to query and
retrieve standard biological
parts for research and use in
synthetic biology.
A DNA design and assembly
platform for Bio CAD/CAM
systems
An application for bringing
together models, information
and algorithms.

http://www.sbolstandar
d.org/sbol-inuse/sbpkb

https://www.teselagen.
com
http://www.tinkercell.c
om

C. Biosecurity Standards Setting
The development and implementation of standards for
biosecurity has been of paramount importance in the field of synthetic
biology. As in other fields, research in synthetic biology may
generate “dual use” findings that could be socially beneficial, such as
new therapies, diagnostic methods, crops, and industrial processes, as
well as harmful, such as new pathogens, toxins, or biological
weapons. Consequently, an early topic of discussion and planning
among the synthetic biology community was how to minimize the
risk of harmful applications of the technology. As early as 2005,
researchers, policy analysts and security experts in universities,
research institutions, commercial firms, and government
organizations have worked to develop biosecurity standards for
synthetic biology.
At the first Synthetic Biology conference (SB 1.0), in 2005, there
was some discussion of biosecurity issues among the synthetic
biology community. Leading up to, and during, SB 2.0, in 2006, a
discussion about biosecurity led to a formal proposal that synthetic
biologists adopt a set of community biosecurity standards.105 With
funding from the Carnegie Corporation Foundation and MacArthur
Foundation, Stephen Maurer, Director of the Berkeley Information
Technology and Homeland Security Project, led a project that
103. Galdzicki, supra note 64.
104. Deepak Chandran, Frank T. Bergmann & Herbert M. Sauro, TinkerCell: Modular
CAD
Tool
for
Synthetic
Biology,
J.
BIOL.
ENG.
(Oct.
29,
2009),
http://www.jbioleng.org/content/3/1/19.
105. Synthetic
Biology:
SB2.0/Biosecurity
Resolutions,
OPENWETWARE,
http://openwetware.org/wiki/Synthetic_Biology:SB2.0/Biosecurity_resolutions (last visited Feb.
1, 2014).
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proposed six resolutions related to promoting an ethic of
biosecurity.106 Another effort, funded by the Alfred P. Sloan
Foundation, resulted in the development of a number of policy,
technical, and other options to address the risks and benefits posed by
dual-use nature of synthetic biology research.107
In the wake of SB 2.0, several consortia of DNA synthesis
companies developed their own standards for detecting orders for
DNA sequences of concern (Table 3). The International Consortium
for Polynucleotide Synthesis (ICPS) developed a plan for creating an
effective oversight framework for the DNA synthesis industry.108 A
rival German effort, led by the International Association of Synthetic
Biology (IASB), developed a code of conduct for assessing the safety
of DNA sequence orders that would rely on both (1) automated
searches for matches with sequences of concern (e.g., the U.S. list of
sequences of concern) and (2) human double-checking.109 The
International Gene Synthesis Consortium (IGSC), comprised of the
world's leading gene synthesis companies, established a harmonized
protocol for preventing the misuse of gene synthesis.110 In addition,
the U.S. Department of Health and Human Services (HHS) issued
guidance aimed at reducing the risk that synthetic DNA will be
misused deliberately to create dangerous organisms.111 Efforts to
articulate and refine biosecurity standards for dual-use research in
synthetic biology and other life science fields are ongoing.112

106. Stephen M. Maurer, End of the Beginning or Beginning of the End? Synthetic
Biology’s Stalled Security Agenda and the Prospects for Restarting It, 45 VAL. U. L. REV. 1387
(2011).
107. Michele S. Garfinkel et al., Synthetic Genomics: Options for Governance, 5
BIOSECURITY & BIOTERRORISM, 359 (2007).
108. Bügl, supra note 15.
109. The IASB Code of Conduct for Best Practices in Gene Synthesis, INTERNATIONAL
ASSOCIATION SYNTHETIC BIOLOGY (Nov. 3, 2009), http://www.ia-sb.eu/tasks/sites/syntheticbiology/assets/File/pdf/iasb_code_of_conduct_final.pdf.
110. Harmonized Screening Protocol: Gene Sequence and Customer Screening to
Promote Biosecurity, INTERNATIONAL GENE SYNTHESIS CONSORTIUM (IGSC) (November 18,
2009), http://www.genesynthesisconsortium.org/resources.php.
111. Dep’t of Health and Human Servs., supra note 17.
112. See, e.g., Enhancing Responsible Science: Considerations for the Development and
Dissemination of Codes of Conduct for Dual Use Research, NAT’L SCI. ADVISORY BD. ON
BIOSECURITY
(NSABB),
http://oba.od.nih.gov/oba/biosecurity/documents/COMBINED_Codes_PDFs.pdf (last visited
Feb. 19, 2014).
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Table 3. Biosecurity Standards in Synthetic Biology
Standards Setting
Organization
The International
Consortium for
Polynucleotide
Synthesis (ICPS)
International
Association of
Synthetic Biology
(IASB)

Year
started
2007

International Gene
Synthesis
Consortium
(IGSC)
U.S. Department
of Health and
Human Services
(HHS)

2009

2008

2010

Biosecurity Standards
The ICPS developed a plan for creating
an effective oversight framework for the
DNA synthesis industry.
The IASB established a code of conduct
for best practices in gene synthesis,
which is primarily based on a selfpoliced system among gene synthesis
and assembly firms.
The IGSC developed a harmonized
protocol for gene sequence and customer
screening to prevent the misuse of gene
synthesis.
The HHS recommendations include
screening customers as well as DNA
sequences, follow-up screening as
necessary, and consulting with U.S.
government contacts as needed.

D. Legal Standards Setting
The development of legal standards to enable synthetic biology
researchers to use and share biological parts was first proposed by
Drew Endy in 2005.113 Over several years beginning late in 2008, the
BioBricks Foundation developed a two-part legal agreement designed
to standardize the use and contribution of biological parts, collectively
referred to as the BioBrick Public Agreement (BPA).114 The
BioBrick User Agreement is designed to oblige signors to abide by a
set of rules for using biological parts responsibly. The BioBrick
Contributor Agreement is designed to govern the responsible
contribution of biological parts for others to use. The BPA purports
to impose a legal standard on users and contributors of genetically
encoded functions, and includes provisions on attribution, safety, and

113. Endy, supra note 3, at 450 (“[L]egal standards are needed to define means by which
large collections of parts encoding basic biological functions, from a myriad of sources, can be
easily shared and used in combination to realize many applications.”).
114. The BioBrick Public Agreement (BPA), BIOBRICKS FOUNDATION,
https://biobricks.org/bpa/ (last visited Feb. 19, 2014). For purposes of full disclosure, the
authors wish to note that Andrew W. Torrance contributed to early drafts of the BPA at the
invitation of the BioBricks Foundation.
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intellectual property rights.115 Of special note, contributors who sign
the BioBrick Contributor Agreement promise not to assert any
existing or future intellectual property rights they possess to any parts
they contribute under the contract.116
III. INTELLECTUAL PROPERTY AND SYNTHETIC BIOLOGY
STANDARDS
Four principle types of intellectual property protection are
relevant to the protection of synthetic biology inventions: (1) patent,
(2) trade secrecy, (3) copyright, and (4) trademark. Thus far, only
patent and trade secrecy have played substantial roles in protecting
such inventions, though both copyright and trademark have been
suggested.117 The subject matter protectable by patent or trade
secrecy is broad, spanning such innovations as new DNA, RNA,
polypeptide molecules, genomes, cells, organisms, and a myriad of
methods of using them either singly or in combination. Because trade
secrets are, by their very nature, difficult to catalogue, the discussion
here focuses on patents. Patent protection for DNA molecules, such
as those deposited into the iGEM Registry of Standard Biological
Parts and other publicly available registries of biological parts, will
serve as an additional focus, though the patent law principles
discussed are applicable to other products and methods of synthetic
biology.
A. Patent
The United States Patent and Trademark Office has granted
patents claiming isolated or purified DNA molecules since at least the
1970s.118 The 1990s race to sequence the entire human genome
precipitated a flood of patent applications (many later maturing into
patents) claiming human DNA that peaked around 2000.119 Patenting
DNA has been criticized as being unethical120 and for causing a

115. Id.
116. See Contributors, BIOBRICKS FOUNDATION, https://biobricks.org/bpa/contributors/
(last visited Feb. 19, 2014).
117. Andrew W. Torrance, Synthesizing Law for Synthetic Biology, 11 MINN. J. L. SCI. &
TECH. 629 (2010).
118. Andrew W. Torrance, Gene Concepts, Gene Talk, and Gene Patents, 11 MINN. J. L.
SCI. & TECH. 157 (2010).
119. Id.
120. Tom Hollon, NIH Researchers Receive Cut-Price BRCA Test, 6 NAT. MED. 610
(2000).
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genetic “tragedy of the anticommons.”121 By one account, roughly
20% of known human genes are claimed in a U.S. patent.122
Although a recent empirical study has brought this estimate into
question,123 if such assessments are even somewhat accurate,
synthetic biologists may be at substantial risk of infringing prodigious
numbers of patent claims to DNA sequences. As such, existing patent
rights may encumber the products and methods of synthetic biology.
Since at least 2005, uncertainty has been rising about whether or
not isolated or purified natural-source DNA constitutes legitimate
patentable subject matter. In 2005, a Court of Appeals for the Federal
Circuit panel held that a set of patent claims expressing sequence tags
(ESTs) lacked utility and enablement, casting doubt on the
patentability of partial-gene DNA sequences.124 In 2007, Xavier
Becerra (Democrat Congressman from California) and Dave Weldon
(Republican Congressman from Florida) unsuccessfully championed
passage of the Genomic Research and Accessibility Act.125 Section
106 of this Act would have barred genes from patent eligibility,
stipulating that “[n]otwithstanding any other provision of law, no
patent may be obtained for a nucleotide sequence, or its functions or
correlations, or the naturally occurring products it specifies.”126
Although this proposal has never been passed by the U.S. Congress,
Section 33 of the Leahy-Smith America Invents Act of 2011 did
amend U.S. patent law to ban the patentability of any invention
“directed to or encompassing a human organism.”127 Lacking
legislative history, court interpretation, and formal incorporation into
the U.S. Code, it is as yet unclear what legal influence Section 33 may
have on the patentability of human DNA sequences.
Most relevant to synthetic biology is the litigation initiated in
2009 by the American Civil Liberties Union (ACLU) and its allies
against the biotechnology firm Myriad Genetics, Inc. and the United
States Patent and Trademark Office.128 Myriad Genetics, Inc. owns

121. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 SCIENCE 698 (1998).
122. Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human
Genome, 310 SCIENCE 239 (2005).
123. Christopher M. Holman, Debunking the Myth that Whole-Genome Sequencing
Infringes Thousands of Gene Patents, 30 NAT. BIOTECHNOL. 240 (2012).
124. In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005).
125. Genomic Research and Accessibility Act, H.R. 977, 110th Cong. (1st Sess. 2007).
126. Id.
127. Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284, 340 (2011).
128. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 669 F. Supp. 2d 365
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rights to several patents claiming, among other inventions, human
BRCA1 and BRCA2 gene variants predictive of breast and ovarian
cancer.129 In its initial complaint in an action for declaratory
judgment, the ACLU stated its opposition to the patent-eligibility of
human genes, and challenged “the legality and constitutionality of
granting patents over this most basic element of every person’s
individuality.”130 In March 2010, Judge Sweet, of the Southern
District of New York, decided that genes “containing sequences
found in nature . . . are deemed unpatentable subject matter.”131
Myriad appealed the decision to the Federal Circuit. On July 29,
2011, a panel of three judges largely reversed the lower court, and
restored the patentability of DNA.132
In response, the ACLU filed a petition for a writ of certiorari to
the U.S. Supreme Court, which vacated the Federal Circuit’s decision
on March 26, 2012,133 and instructed that court to reconsider the
patentability issues in light of Mayo v. Prometheus, a patentability
decision the Court had made a week before.134 The patent claims at
issue in Mayo v. Prometheus were directed to methods of diagnosis
using human metabolites, not to DNA molecules per se.135 However,
the Supreme Court clearly signaled its discontent with the Federal
Circuit’s panel decision.136 On August 16, 2012, the same panel of
Federal Circuit judges broadly reaffirmed their earlier panel decision,
again upholding the patent-eligibility of isolated DNA.137 The Court
of Appeals for the Federal Circuit declined to reconsider the panel
decision by rehearing the case en banc, and the case arrived again

(S.D.N.Y. 2009).
129. See, e.g., U.S. Patent No. 5,709,999 (filed Mar. 1995), U.S. Patent No. 5,747,282
(filed June 7, 1995), U.S. Patent No. 5,753,441 (filed Jan. 5, 1996), U.S. Patent No. 5,837,492
(filed Apr. 29, 1996), U.S. Patent No. 6,033,857 (filed Mar. 20, 1998), U.S. Patent No.
5,654,155 (filed Feb. 12, 1996), U.S. Patent No. 5,750,400 (filed Feb. 12, 1997), U.S. Patent No.
6,051,379 (filed Dec. 2, 1997), U.S. Patent No. 6,951,721 (filed Aug. 8, 2001), U.S. Patent No.
7,250,497 (filed June 9, 2003), U.S. Patent No. 6,083,698 (filed Dec. 11, 1997).
130. Complaint at 1, Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 669
F. Supp. 2d 365 (S.D.N.Y. 2009) (No. 09CV04515).
131. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 702 F. Supp. 2d
181, 185 (S.D.N.Y. 2010).
132. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 653 F.3d 1329 (Fed.
Cir. 2011).
133. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012).
134. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012).
135. Id. at 1295.
136. See id. at 1302-03.
137. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 669 F. Supp. 2d,
365 (S.D.N.Y. 2009).
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before the Supreme Court.138 Oral arguments were heard on April 15,
2013, and the Supreme Court issued a decision on June 13, 2013
holding natural, unmodified DNA—even when isolated or purified
from a genome—to be subject matter ineligible for patent
protection.139 Together, the Mayo v. Prometheus and AMP v. Myriad
decisions have rendered nonsynthetic DNA and many of its uses
unpatentable.
Today, most existing patents directed to DNA molecules claim
nucleotide sequences identical or similar to those derived from
naturally occurring genomes. As the cost, speed, and accuracy of
DNA synthesis technology continues to improve, the design and
production of synthetic DNA molecules from nucleotide sequences
created through computer-aided design processes may become more
prominent. Even though the AMP v. Myriad decision has rendered
natural-source DNA unpatentable, human-designed synthetic DNA is
likely to remain patent-eligible. In an amicus curiae brief filed before
the first Court of Appeals for the Federal Circuit panel decision, the
U.S. Department of Justice argued that “isolated but otherwise
unaltered genomic DNA is not patent-eligible subject matter under 35
U.S.C. Section 101,”140 but that DNA molecules that are “the
synthetic results of scientists’ manipulation of the natural laws of
genetics” could be patent-eligible.141 The Supreme Court largely
adopted this reasoning in its AMP v. Myriad decision.142 It is
important to note, however, that the decision addressed only whether
isolated DNA or cDNA molecules constitute patentable subject matter
under 35 U.S.C. Section 101. The Court specifically expressed no
opinion whether cDNA molecules satisfy the other statutory
requirements for patentability such as novelty, non-obviousness, or
enablement/definiteness under 35 U.S.C. Sections 102, 103, and
112.143
Although thousands of patent claims to natural, unmodified
DNA sequences are now firmly in the public domain, there is a strong
prospect that human-designed synthetic DNA will remain patenteligible for the foreseeable future. The full impact of the AMP v.
138. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).
139. Id.
140. Brief for the United States as Amicus Curiae in Support of Neither Party, Ass’n for
Molecular Pathology v. U.S. Patent & Trademark Off., 653 F.3d 1329 (Fed. Cir. 2011) (No.
2010-1406).
141. Id. at 15.
142. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).
143. Id.
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Myriad decision, particularly concerning the validity of patent claims
to synthetic DNA and its uses, will become more apparent as the
lower courts interpret this decision in subsequent cases.
B. Trade Secrecy
Many owners choose to keep the details, or even the very
existence, of their intellectual property secret. Some information is
difficult to protect by trade secrecy, particularly products or services
whose intellectual property is self-disclosing. For example, it would
be difficult to maintain secrecy about the nucleotide sequence of a
synthetic DNA construct due to the ease of reverse engineering that
construct using routine DNA sequencing methods followed by DNA
synthesis. By contrast, trade secrets inherent in a protein product
whose desired functioning depended on a particular folding pattern
would be easier to preserve due to the great difficulty in reverse
engineering tertiary and quaternary structure.144 By the very nature of
this form of intellectual property protection, little is known about the
extent of reliance on trade secrecy across industries or technological
fields, in general, or in synthetic biology, in particular.
In a confluence of patent and trade secrecy law, Section 273 of
the Leahy-Smith America Invents Act added a defense to patent
infringement for prior commercial use of an invention claimed in a
patent not owned by a university.145 This defense is available only for
commercial uses,146 though the patent statute defines such uses to
include premarketing regulatory review147 and nonprofit laboratory
uses.148 Since this amendment to U.S. patent law has yet to be
interpreted by the courts, it is unclear how it might affect patents and
trade secrets in the field of synthetic biology. Nevertheless, it appears
to place a modest limit on how patent rights may affect long-standing
commercial and research uses of synthetic biological products and
processes.

144. The Biologics Price Competition and Innovation Act of 2009, passed as part of the
Patient Protection and Affordable Care Act of 2010, allows the developer of a biologic to
maintain regulatory data exclusivity for at least 12 years after the biologic is licensed by the
FDA. See 42 U.S.C.A. § 262 (West 2014). Specifically, Section 262 grants biologics
developers a new form of data-based exclusive rights in exchange for potential loss of patent
term caused by entry into the market of generic biologics competitors. Id.
145. See Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284, 297-98
(2011).
146. Id.
147. Id.
148. Id.
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C. Copyright
Copyright protection is relevant to standards development in
synthetic biology in several respects. The documents created to
describe technical standards, such as those of the BioBricks
Foundation’s RFC process, are subject to copyright protection.
Software tools developed for synthetic biology applications, including
the SBOL standard, also are subject to copyright protection. A third
way in which copyright protection may be relevant to standards
development in synthetic biology is the potential for copyright
protection of DNA sequences.
Copyright eligibility for DNA sequences has been discussed for
many years.149 Though not all scholars agree, the case has been made
that synthetic DNA sequences may be especially strong candidates for
copyright protection, in part because the deliberate design of
nucleotide sequences allows considerable scope for creative
expression.150 For example, when Synthetic Genomics synthesized
the first mycoplasma genome, it included several decipherable
sentences among within the genome.151 At least one firm has already
asserted copyright protection for synthetic DNA sequences,152
although to date there has been no litigation.
Copyright affords legal protection against unauthorized copying
for “original works of authorship fixed in any tangible medium of
expression, now known or later developed”.153 In addition to
conventional targets for protection, such as books and paintings,
copyright law has proved capable of adapting to cover additional
forms of creative expression like architecture and computer
149. Duncan M. Davidson, Common Law, Uncommon Software, 47 U. PITT. L. REV. 1037,
1104-05 (1986); Irving Kayton, Copyright in Living Genetically Engineered Works, 50 GEO.
WASH. L. REV. 191 (1982); Donna Smith, Comment, Copyright Protection for the Intellectual
Property Rights to Recombinant Deoxyribonucleic Acid: A Proposal, 19 ST. MARY’S L.J. 1083,
1096-1108 (1988); Dan L. Burk, Copyrightability of Recombinant DNA Sequences, 29
JURIMETRICS J. 469, 531-32 (1989); Andrew W. Torrance, DNA Copyright, 46 Val. U. L.
REV. 1, (2011); Christopher M. Holman, Copyright for Engineered DNA: An Idea Whose Time
Has Come?, 113 W. VA. L. REV. 699 (2011).
150. See, e.g., Torrance, supra note 149, at 30.
151. Daniel G. Gibson et al., One-Step Assembly in Yeast of 25 Overlapping DNA
Fragments to Form a Complete Synthetic Mycoplasma genitalium Genome, 105 PNAS 20404
(2008).
152. Illumina, Inc. asserts copyright protection for some of the oligonucleotide primers
compatible with its DNA sequencing machines in a letter it has sent to customers. Letter from
Illumina, Inc. to Illumina, Inc. customers (Sept. 7, 2012), available at
http://supportres.illumina.com/documents/myillumina/6378de81-c0cc-47d0-9281724878bb1c30/2012-09-18_illuminacustomersequenceletter.pdf (last visited March 4, 2014).
153. 17 U.S.C. § 102 (2012).
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software.154 Like patent protection, copyright protection for DNA
sequences originating in naturally occurring genomes is least
justifiable. The case for copyright protection would likely strengthen
as a DNA sequence of interest acquired more characteristics of human
design and synthetic production. Of course, the case for copyright
protection would be far weaker for DNA sequences designed using
directed evolution approaches since DNA sequences would evolve as
a consequence of natural selective processes and not as a result of
DNA sequence design by human authors.155
Copyright eligibility for DNA sequences, were it available,
would create a much quicker and cheaper route to protection than
does patent protection, and the resulting protection could last almost
an order of magnitude longer. On the other hand, doctrines such as
fair use could permit more uses by others—especially for purposes of
scholarship or education—of copyrighted DNA sequences than does
patent protection, and a DNA copyright framework might allow the
application of open source principles to synthetic biology. 156 Now
that natural-source DNA molecules have lost their eligibility for
patent protection, copyright stands ready to provide an existing
alternative form of protection. Nevertheless, copyright eligibility for
DNA sequences remains uncertain and untested.
D. Trademark
Trademark protection may be available for a mark that indicates
a single origin for goods or services bearing that mark.157 Trademark
law imposes few restrictions on eligible subject matter, as long as the
mark achieves its purpose as an indicator of origin, and customer
confusion is avoided.158 Even synthetic DNA sequences might
qualify as trademarks if they were used in commerce, and served as
designations of origin for products or services.

154. 17 U.S.C. § 101 (2012); 17 U.S.C. § 117 (2012).
155. Directed evolution, like natural evolution, involves the mutation of nucleic acid
sequences followed by the selection for variants that display desirable phenotypes. See Ryan E.
Cobb, Tong Si & Huimin Zhao, Directed Evolution: An Evolving and Enabling Synthetic
Biology Tool, 16 CURRENT OPINION CHEM. BIOL. 285 (2012) (describing advances in the use of
directed evolution in synthetic biology).
156. Note that, as with open source software code, coexistent patent rights could still
create risks of infringement for making, using, selling, offering to sell, or importing synthetic
DNA sequences.
157. See, e.g., ROBERT P. MERGES, PETER S. MENELL & MARK A. LEMLEY,
INTELLECTUAL PROPERTY IN THE NEW TECHNOLOGICAL AGE 735-36 (5th ed. 2010).
158. Id.

TORRANCE & KAHL

228

4/2/2014 11:00 PM

SANTA CLARA HIGH TECH. L.J.

[Vol. 30

The BioBricks Foundation has registered “BioBrick” as a U.S.
trademark.159 Currently, the BioBricks Foundation may use this
trademark as a mild form of leverage to support its standards. In
relevant part, Section 3(a) of the BioBrick User Agreement requires
that “User agrees not to remove or alter any BioBrick identification
tag included in the Materials . . . .”160 The BioBrick Contributor
Agreement defines this aspect of the “Materials” in its preamble as
“the particular standardized genetic material(s) . . . and any associated
sequence . . . information,” and Section 2 of the BioBrick Contributor
Agreement requires contributors to allow the addition of a
“BioBrick™ identification tag” to any genetic material they
contribute.161 If desired, the BioBricks Foundation could assert its
trademark rights more vigorously to promote its BioBrick-related
standards by restricting the descriptor “BioBrick” to only those DNA
molecules fully conforming to specified standards.
E. Synthetic Biology, Biotechnology, and Intellectual Property
Many of the intellectual property issues that arise in specific
context of synthetic biology also pertain to the broader field of
biotechnology. However, synthetic biology differs in its reliance on
approaches from engineering and computer science, including an
emphasis on standards. Due to their unique features, some synthetic
biological inventions may be eligible not only for patent protection,
but also for copyright, and even trademark, protection. Innovations in
synthetic biology may become subject to complicated policy debates
about which forms of intellectual property protection are most
appropriate, just as innovations in software were a generation ago.162
As such, it is important to address the potential confusion surrounding
intellectual property issues in synthetic biology, particularly with

159. “BioBrick” is a registered trademark of the BioBricks Foundation See BIOBRICK,
Registration No. 3836261. It is registered in international classes 41 and 42. Id. Its description
in class 42 is “Research and development services in the fields of biology and biological
engineering; providing information in the fields of biology and biological engineering.” Id.
160. The
BioBrick
User
Agreement,
BIOBRICKS
FOUNDATION,
https://biobricks.org/bpa/users/agreement/ (last visited Jan. 31, 2014) (“User agrees not to
remove or alter any BioBrick™ identification tag or data included in the Materials . . . .”).
161. The
BioBrick
Contributor
Agreement,
BIOBRICKS
FOUNDATION,
http://biobricks.org/wp-content/themes/bbf/bpa-sample.php (last visited Jan. 31, 2014)
(“Contributor agrees that Materials may be modified to include a BioBrick™ identification
tag . . . .”).
162. Arti Rai & James Boyle, Synthetic Biology: Caught between Property Rights, the
Public
Domain,
and
the
Commons,
PLOS
BIOL.
(March
13,
2007),
http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.0050058.
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regards to standards setting initiatives. This must be done in order to
avoid the prolonged uncertainty that could undermine the necessary
commercial investment for bringing useful synthetic biology
applications to market.
CONCLUSIONS
There has been considerable discussion and activity surrounding
standards setting in synthetic biology. This may be due, in part, to the
interdisciplinary backgrounds of many of the field’s leading
participants. A number of institutions within synthetic biology have
made standards setting a priority, and many standards have been
proposed, including those pertaining to the structure, function, and
description of genetic components, data sharing, biosecurity, and law.
Despite this interest in standards, progress in standards setting has
been quite modest so far. Standards for physical assembly of DNA
fragments are continuing to evolve, and methods such as Gibson
Assembly and de novo DNA synthesis are gaining acceptance as
alternate approaches for the construction of large DNA molecules.
Moreover, standards for other technical aspects of synthetic biology
have begun to emerge, including functional composition standards
that support the ability of assembled biological parts to function in a
predictable manner, standards for units of measurement, and data
exchange standards. At the present time, standardization efforts do
not appear to have impeded innovation in synthetic biology and no
single technical standard appears to have dominated the field of
synthetic biology. By comparison, standards covering policies in
biosecurity appear to be better established, and a U.S. governmentproposed biosecurity guidance governing commercial orders for
synthetic DNA has been widely adopted.
Patent rights that encumber components and methods have long
been a concern among those in synthetic biology, especially as a
perceived threat to the field’s prominent ethos of open biological
innovation. Currently, there is little evidence that patent rights
adversely affect synthetic biological research. In fact, the patenteligibility of natural-source DNA molecules has now been ended by
the Supreme Court in its AMP v. Myriad decision, and the new AIA
has created a broadened defense of prior commercial use that offers
some protection from patent infringement for some uses of synthetic
biological products and processes. Copyright and trademark may
provide alternatives mechanisms for conferring rights in synthetic
biological inventions, setting and reinforcing standards, or promoting
open innovation. Among the standards-setting groups that have

TORRANCE & KAHL

230

4/2/2014 11:00 PM

SANTA CLARA HIGH TECH. L.J.

[Vol. 30

formed within the synthetic biology community, most have expressed
a preference that standards remain open and accessible to the
community as a whole. This preference, however, has not yet been
incorporated into formal policies requiring the disclosure and
licensing of intellectual property rights covering technical standards.
Whether such policies could be made mandatory or would ultimately
be beneficial to the field of synthetic biology remain open questions.
What is certain is that the synthetic biology community is unusually
attuned to debates surrounding intellectual property and standards
setting, and views its engagement in these debates as vital to ensure
the continued success of synthetic biology.

